MANE Veradermics, Incorporated
XNYS
122.28
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MANE
$122.28
—
Key stats
$122.28
Pre-market
$127.00
+3.86%
- 52-Week Range
- $32.00 – $136.72
- YTD
- +223.92%
- IV Rank (30D)
- 0.0
- Straddle Price
- $17.65
- P/C Vol Ratio
- 1.14
- Market Cap
- $4.5B
- Open
- $115.34
- Day Range
- $113.00 – $123.93
- Volume
- 1,465,911
- Prev Close
- $108.82
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.10% |
| Beta vs SPY | 0.52 |
| Cost of Equity (CAPM) | 7.68% (VRP-adj) |
| WACC | 8.37% |
| Volatility Risk Premium | -7.6pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $109.42 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $117.44 |
| Bollinger Width / SMA20 | 15.3% (drives anchor stability) |
| Net Debt | $-0.3B |
Peers used for multiples: COGT, CORT, GH, JNJ, LLY, MIRM, SYRE, TVTX
60-Day Conviction
88%
20-Day Fair Value
≈ by Nov 18, 2026
$123.99
α +1.4%
rank 52%
conviction
75%
40-Day Fair Value
≈ by Dec 17, 2026
$125.79
α +2.9%
rank 45%
conviction
81%
60-Day Fair Value
≈ by Jan 15, 2027
$126.54
α +3.5%
rank 39%
conviction
88%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 42.0× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 126.6× · 4 peers |
| Peer P/B | n/a | 0% | median 13.2× · 6 peers |
| Peer P/S | n/a | 0% | median 11.2× · 6 peers |
| Market Anchor (SMA50) | $109.42 | 60% | stability 74% (BB-width) |
| Options Expected (B-L 30d) | $124.83 | 40% | 21 strikes · skew +0.02 |
As of 2026-10-20 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $4.5B
- Employees
- 21
- List Date
- 2026-02-04
- CIK
- 0001827635
- Next Earnings
- 2026-11-10
- EPS Forecast
- ($0.59) (1 est.)
- Headquarters
- New Haven, CT
- Homepage
- https://www.veradermics.com
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | 21.46% | 21.46% |
| Mar | 35.46% | 35.46% |
| Apr | 68.42% | 68.42% |
| May | -0.09% | -0.09% |
| Jun | 21.11% | 21.11% |
| Jul | -18.64% | -18.64% |
| Aug | -3.42% | -3.42% |
| Sep | 24.33% | 24.33% |
| Oct | 4.32%* | 4.32% |
| Nov | -- | -- |
| Dec | -- | -- |
| Total | 241.72% | 241.72% |
* Only 1 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $117.44
SMA 50: $109.42
SMA 200: —
Current: $122.28
EMA 12: $116.89
EMA 26: $114.62
MACD: 2.2657 | Signal: -0.6435
BULLISH
ADX (14): 26.33
TREND
+DI: 27.84
−DI: 17.74
Momentum Oscillators
RSI (14): 56.13
NEUTRAL
Stoch %K: 27.47
Stoch %D: 21.73
Williams %R: -47.79
Volume & Volatility
BB Upper: $127.98
BB Lower: $106.91
NEUTRAL
OBV: 24,194,772
Vol SMA 20: 941,794
Vol ROC: 172.81%
ATR: $8.27
True Range: $15.11
HV 20: 86.5%
HV 30: 77.0%
HV 60: 63.1%
Data Summary
Data Points: 178
Last Updated:
Date Range: 2026-02-04T00:00:00 – 2026-10-19T00:00:00
AI Analysis
Stock Analysis Report: MANE (Mannatech, Inc.)
Executive Summary
Overall Assessment: NEUTRAL | Confidence Level: 6/10
MANE presents a mixed technical picture with bullish momentum indicators offset by price weakness relative to moving averages. The stock is trading $3.08 below its 20-day SMA while showing strong MACD bullish divergence and elevated ADX trend strength, suggesting internal conflict between momentum and price direction. The absence of recent news headlines limits catalyst visibility, while the next earnings report (November 10, 2026) represents the primary forward catalyst. The moderate beta (0.88) and low market correlation (0.13) indicate this is a relatively independent mover with defensive characteristics, though current volatility is elevated.
Key Drivers: Strong MACD bullish signal, elevated trend regime (ADX 29.29), options market pricing substantial expected moves ($29.45 over 37 DTE)
Primary Risks: Price trading below key moving averages, oversold stochastic reading, high historical volatility (78.3% HV20), lack of recent news catalysts, data quality concerns
Investment Thesis: MANE shows technical momentum indicators suggesting potential upside, but price weakness relative to its short-term moving averages creates ambiguity about conviction. The elevated implied volatility and expected move pricing indicate the market is bracing for significant price movement, but without current news flow, the directional bias remains unclear.
Technical Analysis
Trend Direction
| Timeframe | Direction | Strength | Assessment | |-----------|-----------|----------|------------| | Short-term (1-4 weeks) | MIXED/BEARISH | Moderate | Price below SMA20/SMA50; ADX shows trend but directionally conflicted | | Medium-term (1-3 months) | NEUTRAL | Weak | Price positioning ($113.47) between key averages; EMA12 ($117.58) above current price | | Long-term (3-12 months) | UNABLE TO ASSESS | N/A | SMA200 data unavailable; cannot establish longer-term trend context |
Support/Resistance Levels
| Level | Type | Distance | Significance | |-------|------|----------|--------------| | $117.58 | Resistance (EMA12) | +3.62% | Immediate resistance; price must reclaim for bullish confirmation | | $116.55 | Resistance (SMA20) | +2.71% | 20-day average; key short-term resistance | | $114.37 | Resistance (EMA26) | +0.79% | Very near-term resistance; potential pivot | | $113.47 | Current Price | — | Trading slightly above middle Bollinger Band | | $109.19 | Support (SMA50) | -3.77% | 50-day average; established intermediate support | | $105.16 | Support (BB Lower) | -7.38% | Bollinger Band floor; technical support zone |
Key Pattern: Price is currently compressed between SMA20 resistance above and SMA50 support below, suggesting indecision and potential volatility ahead.
Momentum Signals
RSI (14): 49.35 — NEUTRAL
- Reading sits squarely in neutral zone (30-70), indicating no overbought/oversold extremes
- No clear mean-reversion signal; suggests room to move in either direction
- Not confirming price weakness—relatively balanced momentum despite price decline vs SMAs
MACD: 3.21 / Signal: -0.30 / Histogram: +3.51 — STRONGLY BULLISH
- Critical Signal: Histogram at +3.51 shows MACD is well above its signal line and positive
- This is a classic bullish divergence setup—positive MACD histogram despite price trading below short-term averages
- Suggests underlying momentum building that may not yet be reflected in price
- Interpretation: Potential early-stage bullish setup if price can consolidate and reverse higher
Stochastic Oscillators:
- %K: 30.80 (near oversold territory at 30 threshold)
- %D: 49.21 (higher, suggesting potential oversold bounce)
- K below D: Bearish stochastic setup currently, but %K near support levels suggests potential oversold reversal signal
Williams %R: -83.18 — OVERSOLD
- Extreme oversold reading (-80 to -100 range) indicates strong short-term selling pressure
- Historically, readings this extreme often precede mean-reversion bounces
- Caution: Oversold conditions can persist; not a guaranteed reversal signal on their own
Bollinger Bands Analysis
- Upper Band: $127.93
- Middle Band: $116.55
- Lower Band: $105.16
- Band Width: $22.77 (19.54% between upper and lower)
- Current Position: $113.47 sits slightly above middle band but notably below upper band
- Signal: NEUTRAL — Modest contraction
- The band width suggests volatility is moderate (not compressed for breakout, not extremely expanded)
- Price in middle zone indicates no extreme overbought/oversold conditions at band level
- Room to move toward either band ($6.30 to upper, $8.31 to lower)
Volume Analysis
Volume Trends:
- Current Volume SMA 20: 961,385 shares/day average
- Volume Rate of Change: -29.78% ⚠️ SIGNIFICANT FLAG
- Volume has declined notably from recent average
- Suggests institutional interest may be waning or consolidation period
- Weak volume during price moves can indicate lack of conviction
On-Balance Volume (OBV): 22,718,791.42
- Cumulative volume figure; without trend comparison, difficult to assess directionally
- Would need historical OBV to determine if rising/falling
Interpretation: The -29.78% volume rate of change is concerning—strong technical signals (MACD, ADX) are occurring on below-average volume, which reduces confidence in potential breakout. Volume should ideally expand on directional moves for confirmation.
News & Sentiment Analysis
Recent Headlines Summary
⚠️ DATA QUALITY FLAG: No recent news available
This is a significant limitation for the analysis. Without current news flow, we cannot:
- Identify company-specific catalysts
- Explain the recent price weakness (down $3.08 from SMA20)
- Assess management commentary or guidance changes
- Evaluate competitive or regulatory developments
Sentiment Assessment
UNABLE TO ASSESS — Insufficient Data
The absence of news makes sentiment scoring impossible. This creates analytical risk, as price movements without corresponding news context are harder to interpret.
Catalyst Identification
Confirmed Catalysts:
-
Earnings Announcement: November 10, 2026 (284 days forward)
- Primary forward catalyst on calendar
- Expected move from options market ($29.45 over 37 DTE) suggests meaningful volatility priced in, though this timing extends beyond current earnings date
- Note: Recent earnings occurred August 11, 2026—approximately 3 months prior to next report
-
Options Expiration (37 DTE mentioned) suggests near-term catalyst window, likely September 2026
Missing Catalyst Information:
- Product launches or announcements
- Regulatory updates
- Partnership news
- Management changes
- Analyst actions (upgrades/downgrades)
- Industry conference presentations
Market Narrative
CONFLICTED/UNCLEAR
Without news context, the technical narrative becomes difficult to contextualize:
- Bullish Technical Case: MACD bullish divergence, ADX trend strength (29.29), positive histogram suggest momentum building
- Bearish Price Action: Trading $3.08 below SMA20, below EMA12, volume declining
- Unresolved Question: Are technicals leading on recovery, or lagging on further decline?
The mismatch between strong momentum indicators and weak price positioning relative to moving averages suggests the market may be digesting negative information (absent from headlines) or setting up for technical reversal.
Risk & Volatility Assessment
Beta Interpretation: 0.88 (Defensive Characteristics)
Analysis:
- Beta of 0.88 indicates MANE is less volatile than the broader market (SPY)
- For every 1% move in SPY, MANE typically moves approximately 0.88%
- This is defensive positioning—lower market-beta stocks typically outperform during market downturns
- However: This contradicts current
Generated
News
All MANE news →
Earnings History
1 of 1 under expected move
Avg Expected Move
11.01%
Avg Actual Move
0.09%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-11 | unknown | 11.01% | 0.09% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MANE Options Activity & IV Rank
MANE IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 58.4%
7-DTE IV: —
Expected Move: $17.65
7-DTE Move: $17.65
Days to Exp: 32 (2026-11-20)
Options Flow
Call Volume: 83
Put Volume: 95
P/C Volume: 1.145
NEUTRAL
Call OI: 631
Put OI: 317
P/C OI: 0.502
Total OI: 948
ATM Options Pricing
ATM Call: $10.45
ATM Put: $7.20
Call %: 8.5%
Put %: 5.9%
Chain Summary
Chain Volume: 434
Chain OI: 1,642
Last Updated: 10/19/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 98th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
98%
vs own history
GEX tilt
+0.61
OI-weighted, today
Vanna tilt
+0.65
δ-sensitivity to IV
Charm tilt
-0.67
δ-decay vs time
Vanna tilt +0.65: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.67: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 13 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 19 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 19 · ATM 60.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)0.0LowOct 19
Straddle Price (30 DTE)$17.65Oct 19
Beta Analysis
Risk Metrics
Beta: 0.9626
Alpha: 191.75%
Correlation: 0.1366
R-Squared: 1.9%
Stock Volatility: 93.8%
Market Volatility: 13.3%
Analysis Details
Benchmark: SPY
Data Points: 177
Period: 252 trading days
Data Points: 177
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
MANE Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 40,436,264 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
MANE Insider Trading (Form 4)
Latest: 2026-09-03Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | David Hollander | Chief R&D Officer | Award (A) | +9,650 | — | EDGAR | |
| 2026-08-21 | Aaron Cowen | Mixed | −1,800,000 | $107.25 | -$321.75M | EDGAR | |
| 2026-08-18 | Timothy August Durso | Chief Technical Officer | Mixed | −40,048 | $100.79 | -$4.65M | EDGAR |
| 2026-08-18 | Reid Alexander Waldman | Chief Executive Officer | Mixed | −64,048 | $103.21 | -$7.24M | EDGAR |
| 2026-08-14 | John W Childs | Director | Sell (S) | −100,000 | $107.12 | -$10.71M | EDGAR |
| 2026-05-05 | Averill Master Fund, Ltd. | Director | Grant (A) | +1,200,000 RSU | — | EDGAR | |
| 2026-02-27 | John W Childs | Director | Buy (P) | +294,117 | $17.00 | $5.00M | EDGAR |
| 2026-02-09 | SUVRETTA CAPITAL MANAGEMENT, LLC | Director | Buy (P) | +1,130,696 | $37.30 | $42.17M | EDGAR |
| 2026-02-05 | Michael V. Greco | General Counsel | Grant (A) | +144,401 opt | — | EDGAR | |
| 2026-02-05 | David Matthew Friedman | Director | Grant (A) | +43,000 opt | — | EDGAR | |
| 2026-02-05 | Dominic Gabriel Carrano | Chief Financial Officer | Grant (A) | +148,011 opt | — | EDGAR | |
| 2026-02-05 | Katarina Pance | Director | Grant (A) | +43,000 opt | — | EDGAR | |
| 2026-02-05 | Jane M. Grant-Kels | Director | Conv (C) | +2,455 | — | EDGAR | |
| 2026-02-05 | Patrick G Enright | Director | Mixed | +4,653,873 | $17.00 | $18.27M | EDGAR |
| 2026-02-05 | Timothy August Durso | Chief Technical Officer | Conv (C) | +1,473 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MANE Insider Holdings
10 insiders · @ $122.28
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | Director | 3,525,462 | $431.09M | $42.17M | 1 | 2026-02-09 |
| 2 | Patrick G Enright | Director | 2,407,752 | $294.42M | $18.27M | 1 | 2026-02-05 |
| 3 | Longitude Capital Partners V, LLC | 10%+ Owner | 2,407,752 | $294.42M | $73.10M | 1 | 2026-02-05 |
| 4 | John W Childs | Director | 1,907,889 | $233.30M | -$711.7K | 3 | 2026-08-14 |
| 5 | Aaron Cowen | 612,033 | $74.84M | -$321.75M | 1 | 2026-08-21 | |
| 6 | Vlad Coric | Director | 390,514 | $47.75M | $2.00M | 1 | 2026-02-05 |
| 7 | Timothy August Durso | Chief Technical Officer | 194,859 | $23.83M | -$4.69M | 2 | 2026-08-18 |
| 8 | Reid Alexander Waldman | Chief Executive Officer | 170,824 | $20.89M | -$7.28M | 2 | 2026-08-18 |
| 9 | David Hollander | Chief R&D Officer | 9,650 | $1.18M | $0 | 1 | 2026-09-03 |
| 10 | Jane M. Grant-Kels | Director | 2,455 | $300.2K | $0 | 1 | 2026-02-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MANE Proposed Insider Sales (Form 144)
Latest: 2026-08-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
7 filings
· $151.1M notice value
· 7 unique filers
· 14% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Averill Master Fund, Ltd. (1, $74.1M) · SR One Capital Fund II Aggregator, LP (1, $23.7M) · Reid Alexander Waldman (1, $15.0M) · AMZL, LP (1, $11.4M) · John W. Childs 2013 Revocable Trust (1, $10.9M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Averill Master Fund, Ltd. | Affiliate | 690,601 | $74.07M | 2026-08-19 | BofA Securities, Inc. | — | EDGAR |
| 2026-08-19 | Averill Madison Master Fund, Ltd. | Affiliate | 59,399 | $6.37M | 2026-08-19 | BofA Securities, Inc. | — | EDGAR |
| 2026-08-17 | Timothy Durso | Officer | 87,000 | $9.68M | 2026-08-17 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-08-17 | Reid Alexander Waldman | CEO | 135,000 | $15.02M | 2026-08-17 | J.P. Morgan Securities LLC | — | EDGAR |
| 2026-08-14 144/A | John W. Childs 2013 Revocable Trust | Affiliate | 100,000 | $10.90M | 2026-08-12 | Glen Eagle Wealth LLC | — | EDGAR |
| 2026-08-12 | AMZL, LP | Shareholder | 104,587 | $11.39M | 2026-08-12 | Merrill Lynch | — | EDGAR |
| 2026-08-12 | SR One Capital Fund II Aggregator, LP | Shareholder | 217,162 | $23.66M | 2026-08-12 | Merrill Lynch | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
43 ETFs hold MANE
25 shown · $320.89M total exposure · 0.06% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $97.1M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.08% | $61.7M | $74.8B | 2026-10-16 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.05% | $42.9M | — | 2026-09-30 |
| 4 | JGRO JPMorgan Active Growth ETF | JPMorgan | 0.21% | $20.2M | $9.8B | 2026-10-19 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.09% | $15.6M | — | 2026-09-30 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.12% | $15.2M | $13.3B | 2026-10-16 |
| 7 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.76% | $11.5M | $1.5B | 2026-10-16 |
| 8 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 2.29% | $10.1M | $441.7M | 2026-10-16 |
| 9 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.04% | $9.5M | — | 2026-05-31 |
| 10 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.05% | $7.0M | $13.5B | 2026-10-16 |
| 11 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $4.5M | $96.3B | 2026-10-16 |
| 12 | FPX First Trust US Equity Opportunities ETF | First Trust | 0.32% | $4.3M | $1.4B | 2026-10-16 |
| 13 | LFSC F/m Emerald Life Sciences Innovation ETF | Nport | 3.42% | $3.6M | — | 2026-05-31 |
| 14 | TOS Twin Oak Strategic Solutions ETF | Nport | 1.98% | $3.0M | — | 2026-05-31 |
| 15 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.03% | $2.2M | $6.5B | 2026-10-16 |
| 16 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $2.2M | — | 2026-09-30 |
| 17 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.12% | $2.0M | — | 2026-09-30 |
| 18 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.05% | $1.9M | $4.1B | 2026-10-16 |
| 19 | RSSL Global X Russell 2000 ETF | Global X | 0.09% | $1.3M | — | 2026-10-19 |
| 20 | BBSC JPMorgan BetaBuilders U.S. Small Cap Equity ETF | JPMorgan | 0.18% | $1.3M | $715.2M | 2026-10-19 |
| 21 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $1.1M | — | 2026-05-31 |
| 22 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.06% | $772,599 | — | 2026-09-30 |
| 23 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.02% | $748,464 | $3.8B | 2026-10-16 |
| 24 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $638,120 | $20.4B | 2026-10-16 |
| 25 | FSML Franklin Small Cap Enhanced ETF | Franklin | 0.31% | $452,436 | $147.1M | 2026-10-19 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (1 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-23.50M | $-0.58 | $-14.49M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.24M
SI % of Float
17.41%
Days to Cover
4.68
Short Vol Ratio
69.7%
Free Float
24.37M
Float %
58.3%
Short interest 2026-09-30 • Short volume 2026-10-19 • Float 2026-08-24